

Financial Tear Sheet

Corporate Profile

Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives, while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular disease and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the US Headquarters is in Princeton, NJ and the Ireland Headquarters is in Dublin, Ireland.


Primary IR Contact

Nichol Ochsner
 Executive Director, Investor
 Relations & Corporate
 Communications
Phone: 732-754-2545
E-mail:
nochsner@aralez.com

Stock Performance

ARLZ (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$0.39
Change (%)	▼ 0.01 (2.50%)
Volume	468,041
52 Week Low	\$0.36
Market Cap	\$27,159,927
Rolling EPS	-1.76
PE Ratio	0
Shares Outstanding	67,194,277

Data as of 05/24/18 12:55 p.m. ET



Recent Headlines & Events

- 05/08/18 [Aralez Announces First Quarter 2018 Financial Results](#)
- 05/08/18 [Aralez Announces New Strategic Direction](#)
- 04/27/18 [Aralez To Announce First Quarter 2018 Results On May 8, 2018](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
05/18/18	DEFA14A
05/18/18	DEF 14A
05/16/18	4
05/16/18	4

Corporate Governance

Neal F. Fowler

Arthur S. Kirsch

Kenneth B. Lee, Jr.

Seth A. Rudnick, M.D.

F. Martin Thrasher

Adrian Adams

Rob Harris

Data provided by Nasdaq. Minimum 15 minutes delayed.